Presently available biosimilars in hematology-oncology: G-CSF.
about
michGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsBiosimilars in the management of neutropenia: focus on filgrastimSoluble prokaryotic overexpression and purification of bioactive human granulocyte colony-stimulating factor by maltose binding protein and protein disulfide isomerase.A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.Expression of the functional recombinant human glycosyltransferase GalNAcT2 in Escherichia coliSimplified large-scale refolding, purification, and characterization of recombinant human granulocyte-colony stimulating factor in Escherichia coli.Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimensMobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Clinical trials for authorized biosimilars in the European Union: a systematic review.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.Clinical experience with Zarzio® in Europe: what have we learned?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationG-CSF: filgrastim, lenograstim and biosimilars.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.Enhanced heterologous expression of biologically active human granulocyte colony stimulating factor in transgenic tobacco BY-2 cells by localization to endoplasmic reticulum.Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis.Enhanced and Secretory Expression of Human Granulocyte Colony Stimulating Factor by Bacillus subtilis SCK6.Top-down MS for rapid methionine oxidation site assignment in filgrastim.Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
P2860
Q24186266-D4FCB676-57CF-4514-83B8-30F840DA50D8Q24200850-3599D805-52BA-4661-8D77-C6F0A833B823Q26764906-2EA2884A-1218-4879-B563-051B1C9D1DF8Q31152401-3BEE8DC8-6789-4414-8CEF-136079D422F7Q34333814-4773933F-1745-41F5-8AA3-E92453A5434FQ34987860-B5BCEC62-EA53-434C-80AD-338AFC2D4625Q35041617-BFDAC596-EEA0-40AE-ADCF-2F87F1ABA17BQ36000209-AAB652AF-4505-437E-B2B5-8C9B1D738791Q36187379-ECE2066B-A48A-4112-AE16-48CBE2EBF6B6Q36981948-48950AB5-F703-4C76-9B7E-2BC75E49F221Q37373201-4657A0E8-E08A-4095-B1DF-7315BB9A4E65Q37399588-C6F653FC-CB0C-43D2-81EB-4316B25B4E0AQ37616966-9D09E442-8729-4941-B967-514A4EF117D4Q38068457-C9FEED26-39D5-4688-9AEF-36B0E8B8709AQ38125609-DEF762B5-8EDF-4BFD-8EBE-0070D4533F9DQ38186025-3D8AC305-59C1-42D2-ABB5-8041F0EA1E51Q38202661-315CA120-A6FD-4471-911E-F6572DE71148Q38225700-3101F07D-54B6-4ECC-8DC8-050223DF95B0Q38269589-2F99BEE2-5EB6-4615-B335-B5E078A136A1Q38726241-8FCEB16E-91EA-4236-B72C-0526855C9FBAQ38969947-17480955-1BAB-41C2-AF9C-29A0B5BE268BQ38993249-CDB29DC1-6506-4F77-978A-F79506EF9629Q41547224-AA7AFDFD-F6C9-4BDB-A952-CB65F965A3F2Q41907097-8D771F0D-98AE-4CA8-98F7-5E066AC5DD3DQ41976373-72542234-7091-42E9-9CE4-17CF98A70C7CQ46922809-99AC9866-DCEF-4B8E-B035-DAC8B2519B4FQ50112937-685D1239-C189-4BA9-AA54-62F39AC1003FQ51149892-74CCBE44-79A9-4C4F-9C51-E9AF1AA62730
P2860
Presently available biosimilars in hematology-oncology: G-CSF.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Presently available biosimilars in hematology-oncology: G-CSF.
@en
Presently available biosimilars in hematology-oncology: G-CSF.
@nl
type
label
Presently available biosimilars in hematology-oncology: G-CSF.
@en
Presently available biosimilars in hematology-oncology: G-CSF.
@nl
prefLabel
Presently available biosimilars in hematology-oncology: G-CSF.
@en
Presently available biosimilars in hematology-oncology: G-CSF.
@nl
P2860
P1433
P1476
Presently available biosimilars in hematology-oncology: G-CSF.
@en
P2093
Pere Gascon
P2860
P2888
P304
P356
10.1007/S11523-011-0190-9
P478
P577
2012-01-19T00:00:00Z
2012-03-01T00:00:00Z